In a 31-year-old woman with polycystic ovary syndrome and elevated total testosterone (85 ng/dL) and free testosterone (4.5 pg/mL) presenting with chronic diffuse hair loss without scalp lesions, what further evaluation is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Further Evaluation for 31-Year-Old Woman with PCOS and Elevated Androgens Presenting with Diffuse Hair Loss

Based on the 2019 Androgen Excess and PCOS Society guidelines, you should obtain: thyroid function tests (TSH, free T4), prolactin, iron studies (ferritin), vitamin D (25-hydroxyvitamin D), and zinc levels 1.

Recommended Laboratory Workup

The androgen evaluation is already complete with total and free testosterone measured. The next step focuses on identifying treatable conditions that impair hair regrowth:

Mandatory Additional Testing

  • Thyroid profile (TSH, free T4): While thyroid disorders don't occur more frequently in FPHL patients than the general population, hypothyroidism can cause telogen effluvium that prevents hair regrowth even when treating the primary condition 1

  • Prolactin: 7.2% of FPHL patients have elevated prolactin, with 1.8% having prolactinomas in prospective studies 1

  • Iron studies (serum ferritin): 29% of FPHL patients show ferritin deficiency at initial consultation, though the relationship between iron deficiency and FPHL remains uncertain 1

  • Vitamin D (25-hydroxyvitamin D): 62% of FPHL patients present with low vitamin D levels 1

  • Zinc levels: 15% of FPHL patients have low zinc levels 1

Rationale for This Approach

The guidelines explicitly state that "measurements of blood iron studies, vitamin D, zinc, thyroid profile, and prolactin may be useful to rule out and treat other conditions that may affect hair regrowth in FPHL" 1. While these deficiencies may not cause FPHL directly, they create barriers to successful treatment response.

Important Caveats

The evidence for nutritional deficiencies is mixed: While vitamin D, iron, and zinc deficiencies are frequently found in FPHL patients, well-controlled studies demonstrating that correction improves hair growth are lacking 1. However, identifying and treating these conditions is still recommended because:

  • They are common in this population
  • They may impair response to primary FPHL treatments
  • They have minimal risk when corrected appropriately

Regarding iron specifically: The relationship remains controversial. Some studies show lower ferritin in FPHL patients (especially those with severe hair loss), while others show no significant difference from controls. One study found that iron supplementation in patients with low-normal ferritin (<70 mg/L) did not improve hair loss 1.

What You've Already Accomplished

Your patient's androgen assessment is complete with total testosterone (85 ng/dL) and free testosterone (4.5 pg/mL) already measured. The guidelines recommend high-quality assays (LC/MS or immunoassay with extraction) for total testosterone and direct measurement or calculation using SHBG for free testosterone 1. These values confirm hyperandrogenism in the context of PCOS.

Clinical Examination Considerations

While not laboratory testing, ensure you've performed:

  • Scalp examination to differentiate FPHL from other causes (you've noted no scalp lesions or irritation, which is consistent with FPHL)
  • Dermatoscopic examination may be needed if the diagnosis is unclear, though your clinical presentation appears straightforward 1

The absence of scalp lesions or irritation makes cicatricial alopecias (scarring hair loss) unlikely, supporting the diagnosis of FPHL in the context of PCOS with hyperandrogenism.

References

Related Questions

In a woman with irregular menses (oligo/anovulation) and facial hirsutism but no signs of virilism, should we initiate therapy without further investigation or first screen for polycystic ovary syndrome (PCOS) and serum testosterone level?
A 28-year-old woman with a two-year history of irregular menses, polycystic-appearing ovaries on ultrasound, and elevated serum testosterone—does she meet criteria for polycystic ovary syndrome (PCOS) and what management recommendations should be pursued?
Is testosterone reduction indicated in a 28-year-old woman with polycystic ovary syndrome who is attempting pregnancy?
Can Mirena (levonorgestrel) cause alopecia?
In a 40‑year‑old woman with elevated dehydroepiandrosterone sulfate (DHEA‑S) and testosterone, what is the appropriate diagnostic work‑up and initial management?
Can a female patient on benazepril, amlodipine, metformin, ezetimibe, citalopram, loratadine, pantoprazole, meloxicam as needed, fluconazole single dose, and other medications be started on a statin?
What is the first-line antibiotic for a male patient with urinary tract infection symptoms and a urinalysis showing leukocytes and nitrites?
How should I interpret iron studies showing serum iron 50 µg/dL, total iron‑binding capacity (TIBC) 279 µg/dL, transferrin saturation 18 %, and unsaturated iron‑binding capacity (UIBC) 229 µg/dL, and what is the recommended management?
What are the recommended drug treatments for a large patent ductus arteriosus (PDA) in a newborn?
What is Eliquis (apixaban) used for?
What do anti‑Ro (SSA), anti‑La (SSB), and anti‑Sa antibodies test for?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.